Cite
HARVARD Citation
Prica, A. et al. (2015). Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced‐stage follicular lymphoma: A cost‐effectiveness analysis. Cancer. 121 (15), pp. 2637-2645. [Online].